Literature DB >> 17904523

The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity.

Hiroaki Higashitsuji1, Hisako Higashitsuji, Yu Liu, Tomoko Masuda, Takanori Fujita, H Ismail Abdel-Aziz, Supranee Kongkham, Simon Dawson, R John Mayer, Yoshito Itoh, Toshiharu Sakurai, Katsuhiko Itoh, Jun Fujita.   

Abstract

Gankyrin is an oncoprotein commonly overexpressed in hepatocellular carcinomas. It interacts with multiple proteins and accelerates degradation of tumor suppressors Rb and p53. Since gankyrin consists of 7 ankyrin repeats and is structurally similar to IkappaBs, we investigated its interaction with NF-kappaB. We found that gankyrin directly binds to RelA. In HeLa and 293 cells, overexpression of gankyrin suppressed the basal as well as TNFalpha-induced transcriptional activity of NF-kappaB, whereas down-regulation of gankyrin increased it. Gankyrin did not affect the NF-kappaB DNA-binding activity or nuclear translocation of RelA induced by TNFalpha in these cells. Leptomycin B that inhibits nuclear export of RelA suppressed the NF-kappaB activity, which was further suppressed by gankyrin. The inhibitory effect of gankyrin was abrogated by nicotinamide as well as down-regulation of SIRT1, a class III histone deacetylase. Thus, gankyrin binds to NF-kappaB and suppresses its activity at the transcription level by modulating acetylation via SIRT1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904523     DOI: 10.1016/j.bbrc.2007.09.072

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Assembly, structure, and function of the 26S proteasome.

Authors:  Lynn Bedford; Simon Paine; Paul W Sheppard; R John Mayer; Jeroen Roelofs
Journal:  Trends Cell Biol       Date:  2010-04-26       Impact factor: 20.808

Review 2.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

3.  Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK.

Authors:  Ping Qiu; Michelle Kurpakus Wheater; Yue Qiu; Gabriel Sosne
Journal:  FASEB J       Date:  2011-02-22       Impact factor: 5.191

Review 4.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

5.  IKKbeta specifically binds to P16 and phosphorylates Ser8 of P16.

Authors:  Yi Guo; Chunhua Yuan; Christopher M Weghorst; Junan Li
Journal:  Biochem Biophys Res Commun       Date:  2010-02-10       Impact factor: 3.575

Review 6.  Gankyrin regulates cell signaling network.

Authors:  Xinxin Wang; Bin Jiang; Yanjie Zhang
Journal:  Tumour Biol       Date:  2016-01-27

7.  Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.

Authors:  Ju-Ae Hwang; Heung-Mo Yang; Doo-Pyo Hong; Sung-Yeon Joo; Yoon-La Choi; Joo-Hung Park; Alexander J Lazar; Raphael E Pollock; Dina Lev; Sung Joo Kim
Journal:  Oncotarget       Date:  2014-10-15

Review 8.  Structural Insights into Ankyrin Repeat-Containing Proteins and Their Influence in Ubiquitylation.

Authors:  Emma I Kane; Donald E Spratt
Journal:  Int J Mol Sci       Date:  2021-01-09       Impact factor: 5.923

9.  Gankyrin modulated non-small cell lung cancer progression via glycolysis metabolism in a YAP1-dependent manner.

Authors:  Tong Yu; Yanyan Liu; Junwen Xue; Xiang Sun; Di Zhu; Lu Ma; Yingying Guo; Tongzhu Jin; Huiying Cao; Yingzhun Chen; Tong Zhu; Xuelian Li; Haihai Liang; Zhimin Du; Hongli Shan
Journal:  Cell Death Discov       Date:  2022-07-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.